AngioDynamics, Inc. (NASDAQ:ANGO) Stake Lifted by First Eagle Investment Management LLC

First Eagle Investment Management LLC increased its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 4.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 410,335 shares of the medical instruments supplier’s stock after acquiring an additional 16,221 shares during the period. First Eagle Investment Management LLC owned approximately 1.01% of AngioDynamics worth $3,759,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Rhumbline Advisers boosted its holdings in shares of AngioDynamics by 1.7% in the fourth quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier’s stock valued at $554,000 after acquiring an additional 1,021 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in AngioDynamics by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 329,090 shares of the medical instruments supplier’s stock valued at $3,014,000 after purchasing an additional 2,270 shares during the last quarter. Quarry LP lifted its stake in AngioDynamics by 40.9% during the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock valued at $66,000 after purchasing an additional 2,471 shares during the last quarter. SG Americas Securities LLC lifted its stake in AngioDynamics by 21.3% during the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock valued at $147,000 after purchasing an additional 2,832 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in AngioDynamics during the fourth quarter valued at approximately $28,000. 89.43% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright increased their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, January 10th.

AngioDynamics Stock Performance

Shares of NASDAQ:ANGO opened at $9.01 on Friday. The company has a market cap of $364.60 million, a PE ratio of -1.60 and a beta of 0.57. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $13.50. The firm has a 50 day simple moving average of $10.82 and a 200 day simple moving average of $8.63.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07. The business had revenue of $72.90 million during the quarter, compared to the consensus estimate of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The firm’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.05) EPS. On average, equities analysts predict that AngioDynamics, Inc. will post -0.37 earnings per share for the current year.

Insider Activity at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the sale, the senior vice president now owns 41,817 shares in the company, valued at approximately $514,767.27. This represents a 8.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.40% of the stock is owned by insiders.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.